Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Triazolam

FDA-approved product (tablet, oral), marketed as Halcion, Triazolam.

Registered studies
17
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Triazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

17registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Triazolam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Triazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

    NCT06837142 · start 2025-03-11

    Registered record
    Registry ID
    NCT06837142
    Conditions
    Healthy Male Subjects
    Interventions
    Triazolam and TS-172; TS-172 and itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-03-11
    Completion
    2025-04-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male Subjects
    InterventionTriazolam and TS-172; TS-172 and itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal

    NCT03954483 · start 2023-10-16

    Registered record
    Registry ID
    NCT03954483
    Conditions
    Anxiety
    Interventions
    Buspirone 10 Mg Oral Tablet; Triazolam 0.25 MG Oral Tablet; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-10-16
    Completion
    2027-10-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety
    InterventionBuspirone 10 Mg Oral Tablet; Triazolam 0.25 MG Oral Tablet; Placebo oral tablet
    PhaseNot applicable
    Registry statusRecruiting

  • Oral Sedation in Vitreoretinal Surgery

    NCT04346095 · start 2020-06

    Registered record
    Registry ID
    NCT04346095
    Conditions
    Macular Holes; Intraocular Lens Opacification; Vitrectomy; Vitreous Hemorrhage; Retinal Detachment; Epiretinal Membrane; Vitreous Detachment; Intraocular Lens Dislocation
    Interventions
    Oral Sedatives with or Without Analgesia; Intravenous Sedatives with or Without Analgesia
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06
    Completion
    2020-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes; Intraocular Lens Opacification; Vitrectomy; Vitreous Hemorrhage +4 more
    InterventionOral Sedatives with or Without Analgesia; Intravenous Sedatives with or Without Analgesia
    PhasePhase 4
    Registry statusUnknown

  • Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient

    NCT03360123 · start 2018-01-26

    Registered record
    Registry ID
    NCT03360123
    Conditions
    Dental Anxiety
    Interventions
    Midazolam Hydrochloride 2Mg/mL Syrup; Triazolam 0.125 MG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-01-26
    Completion
    2018-04-11
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDental Anxiety
    InterventionMidazolam Hydrochloride 2Mg/mL Syrup; Triazolam 0.125 MG
    PhaseNot applicable
    Registry statusCompleted

  • Oral Versus Intravenous Sedation for Ocular Procedures

    NCT03246724 · start 2017-10-16

    Registered record
    Registry ID
    NCT03246724
    Conditions
    Surgery; Sedation
    Interventions
    Triazolam; Midazolam; Microcrystalline Cellulose; Sodium chloride 0.9%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-16
    Completion
    2019-11-30
    Enrolment
    327

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgery; Sedation
    InterventionTriazolam; Midazolam; Microcrystalline Cellulose; Sodium chloride 0.9%
    PhasePhase 4
    Registry statusCompleted

  • Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

    NCT02822937 · start 2016-07

    Registered record
    Registry ID
    NCT02822937
    Conditions
    Healthy
    Interventions
    Methylphenidate; Triazolam; Project: EVO; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2016-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMethylphenidate; Triazolam; Project: EVO; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • Effects of Hallucinogens and Other Drugs on Mood and Performance

    NCT02033707 · start 2014-04

    Registered record
    Registry ID
    NCT02033707
    Conditions
    Healthy
    Interventions
    Hallucinogens and psychoactive substances
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2019-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionHallucinogens and psychoactive substances
    PhasePhase 1
    Registry statusCompleted

  • Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

    NCT01888497 · start 2013-07-29

    Registered record
    Registry ID
    NCT01888497
    Conditions
    Healthy
    Interventions
    Gabapentin; Diphenhydramine citrate; Triazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07-29
    Completion
    2013-12-14
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGabapentin; Diphenhydramine citrate; Triazolam; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

    NCT01780259 · start 2012-12

    Registered record
    Registry ID
    NCT01780259
    Conditions
    Healthy
    Interventions
    Esketamine; Placebo; Triazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-05
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEsketamine; Placebo; Triazolam
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects

    NCT01421043 · start 2011-09

    Registered record
    Registry ID
    NCT01421043
    Conditions
    Healthy
    Interventions
    triazolam liquid oral drops; triazolam tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2011-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontriazolam liquid oral drops; triazolam tablets
    PhasePhase 1
    Registry statusCompleted

  • Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

    NCT01017926 · start 2010-08

    Registered record
    Registry ID
    NCT01017926
    Conditions
    Healthy Volunteers
    Interventions
    Triazolam; Triazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2010-08
    Completion
    2010-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTriazolam; Triazolam
    PhasePhase 1
    Registry statusWithdrawn

  • A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

    NCT00894699 · start 2009-06

    Registered record
    Registry ID
    NCT00894699
    Conditions
    Sedation; Anxiety; Pain
    Interventions
    Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03); Placebo NanoTab™
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-06
    Completion
    2009-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSedation; Anxiety; Pain
    InterventionSublingual Sufentanil/Triazolam NanoTab™ (ARX-F03); Placebo NanoTab™
    PhasePhase 2
    Registry statusCompleted

  • Flumazenil Reversal of Oral Triazolam

    NCT00695630 · start 2006-09

    Registered record
    Registry ID
    NCT00695630
    Conditions
    Dental Anxiety
    Interventions
    Flumazenil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDental Anxiety
    InterventionFlumazenil; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Physiological, Behavioral and Subjective Effects of Drugs (GHB)

    NCT00058955 · start 2003-08

    Registered record
    Registry ID
    NCT00058955
    Conditions
    Sedative Abuse
    Interventions
    sodium oxybate, triazolam and pentobarbital
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-08
    Completion
    2005-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSedative Abuse
    Interventionsodium oxybate, triazolam and pentobarbital
    PhasePhase 1
    Registry statusCompleted